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Abstract The use of NIH3T3 fibroblasts overexpressing 
different mutations of the EGF receptor shows that regulation 
of fructose-2,6-bisphosphate (Fru-2,6-P2) metabolism by EGF is 
mediated by the kinase activity of the EGF receptor and suggests 
a PLCyl -mediated mechanism. The effect of several extracel-
lular matrix components on glucose metabolism was assessed by 
incubating A431 cells and NIH3T3 fibroblasts with heparin, 
laminin, fibronectin, collagen and PG-I and PG-II proteoglycans 
and measuring the levels of Fru-2,6-P2. Laminin increased the 
levels of Fru-2,6-P2 and heparin decreased the levels of the 
metabolite, whereas the other molecules did not have any effect. 
No effect of laminin or heparin in glucose uptake by the cell was 
observed. Laminin was able to modulate the effects of EGF on 
Fru-2,6-P2 concentration, suggesting cross-talk between these 
agents. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Many of the agents which regulate glucose metabolism act 
by altering the levels of fructose-2,6-bisphosphate (Fru-2,6-
P2), the main activator of the key enzyme in the glycolytic 
pathway, P F K - 1 . We have previously described that epider-
mal growth factor (EGF) can stimulate glucose metabolism in 
A431 cells [1]. Fru-2,6-P2 levels are also increased in cells 
treated with other growth promoters such as 12-O-tetradeca-
noylphorbol 13-acetate (TPA) or transfected with several on-
cogenes [2,3], thus indicating that a mechanism exists that 
couples cell growth and ability to obtain energy from glucose. 
Recently, several laboratories have focused their attention 
on the proliferative and morphological effects of the extracel-
lular matrix (ECM) and its interactions with growth factor-
triggered mechanisms, but its role on the control of energy 
metabolism has not been investigated. E C M components can 
affect cellular processes by its ability to bind growth factors [4] 
or by directly activating intracellular signaling pathways that 
modulate cell proliferation, differentiation or migration [5,6]. 
There is increasing evidence that E C M components modulate 
cellular activity through receptor-mediated mechanisms such 
as changes in protein phosphorylation [7-9], gene expression 
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[10] and the generation of intracellular second messengers [11 -
13]. 
Among the E C M components and related molecules, lam-
inin and heparin have been described as potent modulators of 
cell growth. Laminin is a large glycoprotein composed of 
many distinct domains [14] and is able to interact with several 
types of receptors on the cell surface [15]. Laminin has been 
described as a growth factor for many cell types and the 
regions involved in the mitogenic action have been localized 
in the EGF-like motifs from the short arms [16-18]. Heparin 
inhibits the proliferation of several cell types [19,20] and is 
able to modulate the expression of specific genes [21,22]. Re-
cently, heparin has been shown to activate the F G F receptor 4 
independently of the presence of the growth factor [23]. At the 
moment , though, the possibility that E C M molecules could 
exert an effect on the metabolic efficiency of the cell has not 
been investigated. 
The aim of this work was twofold: first, to investigate the 
role of the E G F receptor on the control of Fru-2,6-P2 levels 
by this factor and second, to determine whether glucose me-
tabolism can be regulated by several E C M components. 
2. Materials and methods 
2.1. Materials 
EGF from mouse submaxillary glands, laminin, collagen and fibro-
nectin were from Boehringer Mannheim. Heparin (low molecular 
weight) was from Sigma or from Opocrin S.p.A. Biofarmaci (kindly 
given by Dr. S. Vannucchi, Istituto di Patologia Generale, University 
of Florence, Italy). PG-I and PG-II from bovine bone were kindly 
given by Dr. L.W. Fisher (NIH, Bethesda, MD, USA). Chondroitin 
sulfate was from Sigma. Reagents for cell culture were from Gibco. 
All other reagents were from Boehringer Mannheim or Sigma. 
2.2. Cell culture 
All cell lines were grown at 37°C in the presence of 5% C0 2 in 
Dulbecco's modified Eagle medium containing 10% fetal calf serum 
with 100 IU penicillin/ml and 100 ug/ml streptomycin. A431 human 
epidermoid carcinoma cells were obtained from ATCC (CRL 1555). 
This cell line has been described to contain 2.6 X 106 EGF receptors/ 
cell [24]. The NIH3T3 fibroblasts transfected with several mutations 
of the EGF receptor, pCOll [25], F3 [26], Kin" [27] and Dc214 [27] 
were kindly given by Dr. L. Beguinot (Laboratorio di Oncologia 
Molecolare, H.S. Raffaele, Istituto de Recovero a Cattere Scientifico, 
Milan, Italy). 
2.3. Treatment of the cells with ECM components, EGF and other 
effectors 
Cells were plated in triplicate and the experiments were performed 
48 h after confluence. Under these conditions, cells are quiescent and 
the glycolytic flux is low. Twenty hours before the end of the incuba-
tion, the medium was removed and a low glucose, glutamine-free 
medium containing 6 mM glucose, 126 mM NaCl, 14 mM NaHC0 3 , 
38 mM KC1, 0.9 mM Na 2HP0 4 , 0.6 mM KH2P04 , 0.6 mM MgS04, 
0.3 mM CaCl2, 20 mM HEPES pH 7.2 (incubation medium) was 
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added to the plates with different concentrations of the indicated 
ECM components. After the incubation, the medium was rapidly 
removed and the monolayers immediately frozen in liquid nitrogen 
and stored at — 80°C. The triplicate plates were treated, processed and 
analyzed separately. 
In the case of treatment with EGF, the incubation medium was 
renewed 90 min before adding the factor to eliminate possible secreted 
molecules and restore the initial glucose concentration. 100 ng/ml 
EGF was added to the cells for the indicated times. Controls received 
100 uM acetic acid, as vehicle. 
Down-regulation of protein kinase C (PK-C) was achieved by cul-
turing the monolayers in the presence of 500 nM TPA during the 20 h 
of preincubation in incubation medium [1]. 
2.4. Analytical procedures 
Fru-2,6-P2 was measured in alkaline extracts prepared by adding 
1 ml 50 mM NaOH to 35 mm plates and heating the samples at 80°C 
for 10 min. After centrifugation at lOOOOXg for 10 min, Fru-2,6-P2 
was measured in duplicate in the supernatant by the method described 
by Van Schaftingen et al. [28]. 
The uptake of 2-deoxyglucose was determined as described previ-
ously using 2-deoxy-D-[U-14C]glucose [29]. 
Protein concentration was determined using bovine serum albumin 
as standard. 
3. Results 
3.1. The ejfect of EGF on Fru-2,6-P2 levels depends on the 
kinase activity of the EGF receptor 
EGF increased the levels of Fru-2,6-P2 in pCOll fibroblasts 
transfected with the wild-type EGF receptor in a similar man-
ner as previously described in our laboratory for A431 cells 
(Fig. 1, [1]). The time course showed a maximal increase in 
Fru-2,6-P2 concentration of up to twofold and this value did 
not decrease significantly for at least 4 h (data not shown). 
The EC50 determined in pCOll fibroblasts was 0.3 ng/ml vs. 
10 
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Fig. 1. Effect of EGF on Fru-2,6-P2 levels in NIH3T3 fibroblasts 
expressing different mutations of the EGF-receptor. pCOl 1 (•), F3 
(■), Dc214 (o) and Kin- (□) cells were grown on 24 well plates 
and after 2 days of confluence, they were maintained for 20 h in in-
cubation medium. Two hours before the end of the incubation, dif-
ferent concentrations of EGF or 0.1 mM acetic acid were added to 
the cells. Fru-2,6-P2 was determined in alkaline extracts as described 
in Section 2. The percentage increase from the basal level of Fru-
2,6-P2 is represented (basal values: pCOll: 25.4; F3: 16.9; Dc214: 
76.9; Kin": 3.9 pmol/mg protein). The number of receptors per cell 
is: pCOll: 150000; F3: 250000; Dc214: 70000-150000 and Kin": 
50000-70000. The average of five different experiments is repre-
sented. 
Table 1 
Fru-2,6-P2 levels in A431 cells and EGF receptor-transfected 
NIH3T3 fibroblasts pretreated with laminin and incubated with or 
without EGF 
Cell line 
A431 
pCOll 
F3 
Dc214 
Kin" 
EGF Fru-2,6-P2 (pmol/mg) 
Control 
45.6 ±2.2 
73.7 ±3.9 
25.4 ±0.9 
43.4 ±2.5 
16.4 ±0.9 
25.8 ±1.0 
76.5 ±5.2 
130.2 ±7.5 
3.9±0.1 
4.2 ±0.2 
Laminin (%) 
61.9±3.7 (136) 
76.4 ±2.6 
39.6 ±1.3 (156) 
42.1 ±2.2 
24.4 ±0.8 (149) 
27.1 ±1.6 
115.1 ±6.4 (150) 
132.3 ±7.8 
6.4 ±0.2 (164) 
7.2 ±0.2 
Cells were grown on 24 well plates and after 2 days of confluence, 
they were maintained for 20 h in incubation medium and with or 
without 100 ng/ml laminin. Two hours before the end of the incuba-
tion, 100 ng/ml EGF or 0.1 mM acetic acid were added to the cells. 
Fru-2,6-P2 was determined in alkaline extracts as described in Section 
2 (n = 5). The percentage increase caused by laminin vs. control cells is 
indicated in parentheses. 
30 ng/ml in A431 cells, indicating that fibroblasts were more 
sensitive to EGF, probably because A431 cells have a very 
low proportion of high affinity receptors [30]. 
Several fibroblast cell lines expressing different mutations of 
the EGF receptor were analyzed (Fig. 1 and Table 1). Kin -
fibroblasts, which express a receptor lacking the tyrosine kin-
ase activity, did not respond to EGF. The Dc214 mutants 
have a deletion of 214 carboxy-terminal amino acids, includ-
ing the five putative autophosphorylated tyrosines [27]. In 
these cells, the sensitivity to EGF is lower than in pCOll cells 
in terms of EC50 (30 ng/ml vs. 0.3 ng/ml) and maximal re-
sponse achieved (70% vs. 120%). The F3 receptor mutants 
have the main autophosphorylated tyrosines (Y1173, Y1148 
and Y1068) substituted with phenylalanine [26]. In these cells, 
the EC50 coincided with that from pCOll cells, but the max-
imal response was lower. The numbers of receptors per cell 
expressed in each cell line and the Fru-2,6-P2 basal levels are 
indicated in the legend of Fig. 1. 
3.2. Fru-2,6-P2 levels can also be regulated by several ECM 
components 
To analyze whether the glycolytic response can be modified 
by the ECM, A431 cells were preincubated for 20 h in the 
presence of several ECM components and the level of Fru-2,6-
P2 was determined. As can be observed in Fig. 2, laminin 
increased and heparin decreased the concentration of Fru-
2,6-P2. Other ECM components such as the proteoglycans 
PG-I and PG-II, collagen and fibronectin or chondroitin sul-
Table 2 
2-Deoxyglucose uptake in A431 cells and pCOll fibroblasts pre-
treated with laminin or heparin 
2-Deoxyglucose uptake (nmol/min X mg) 
Control Laminin Heparin 
A431 
pCOll 
0.26 ±0.01 
0.74 ±0.01 
0.24 ±0.01 
0.77 ±0.01 
0.22 ±0.01 
0.73 ±0.01 
Cells were grown on 24 well plates and after 2 days of confluence, 
they were maintained for 20 h in incubation medium and with or 
without 100 ug/ml laminin or 200 ug/ml heparin. 2-Deoxyglucose 
uptake was determined as described in Section 2 (n = 4). 
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Table 3 
Effect of heparin on Fru-2,6-P2 levels in A431 cells and pCOll fi-
broblasts depleted of PK-C 
Cell line Non-depleted (%) PK-C-depleted (%) 
A431 
pCOll 
60.1 ±3.1 
77.2 ±1.9 
64.5 ±3.5 
78.0 ±2.1 
Cells were grown on 24 well plates and after 2 days of confluence, 
they were maintained for 20 h in incubation medium in the absence 
(non-depleted) or presence of 300 nM TPA (PK-C-depleted) and with 
or without 200 ug/ml heparin. Fru-2,6-P2 was determined in alkaline 
extracts as described in Section 2. PK-C depletion was assessed by the 
lack of effect of TPA on Fru-2,6-P2 levels in these cells. 100% is the 
Fru-2,6-P2 level in non-depleted cells in the absence of heparin. The 
average of three different experiments is represented. 
fate did not show any effect. The effect of laminin and heparin 
was dependent on their concentration. The same effects were 
observed in pCOll fibroblasts. Glucose transport inside the 
cells were determined by measuring the uptake of 2-deoxyglu-
cose in the presence of laminin and heparin. No significant 
differences were observed under our experimental conditions 
(Table 2). 
To test whether there is an interaction between laminin and 
the EGF receptor, all the fibroblast cell lines carrying muta-
tions of the EGF receptor were incubated with laminin (Table 
1). In all cases, laminin induced an increase in Fru-2,6-P2 
levels of up to 150% on average. This effect can be seen 
even in the kinase-defective mutants. When cells were pre-
treated for 20 h with laminin before the treatment with 
EGF, it can be observed that the effects of EGF and laminin 
on Fru-2,6-P2 were not additive in any of the cell lines (Table 
1). 
To study whether PK-C and heparin interact at some point 
of their mechanism, A431 cells and pCOll fibroblasts were 
depleted of PK-C by long-term treatment with TPA [1] and 
treated with heparin in the same conditions as above. PK-C 
depletion was assessed by the lack of effect of TPA on Fru-
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Fig. 3. Effect of TPA on Fru-2,6-P2 levels on NIH3T3 fibroblasts 
and A431 cells pretreated with heparin. Cells were grown on 24 well 
plates and after 2 days of confluence, they were maintained for 20 h 
in incubation medium and with or without 200 ug/ml heparin. Two 
hours before the end of the incubation, 150 nM TPA or 0.1% 
DMSO were added to the cells. Fru-2,6-P2 was determined in alka-
line extracts as described in Section 2. The average of three different 
experiments is represented. 
2,6-P2 levels in these cells. Heparin was able to diminish the 
level of Fru-2,6-P2 in PK-C-depleted cells similarly to control 
cells, indicating that PK-C is not directly involved in the 
mechanism of heparin action (Table 3). The acute treatment 
with TPA is able to produce an increase in the level of Fru-
2,6-P2 in pCOll fibroblasts as well as in A431 cells (Fig. 3, 
[1]). Nevertheless, the effect of TPA is lower in heparin-pre-
treated cells, especially in A431 cells where it is completely 
abolished. This fact indicates that heparin is able to modulate 
the PK-C-mediated increase of Fru-2,6-P2 (Fig. 3). 
160 
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Fig. 2. Fru-2,6-P2 levels in A431 cells incubated in the presence of 
several components of the extracellular matrix. Cells were grown on 
24 well plates and after 2 days of confluence, they were maintained 
for 20 h in incubation medium in the presence of several compo-
nents of the ECM at the indicated concentrations (ug/ml). Fru-2,6-
P2 was determined in alkaline extracts as described in Section 2. 
Hep: heparin; Lam: laminin; CS: chondroitin sulfate; PG-I: bigly-
can; PG-II: decorin; Col: collagen; Fib: fibronectin. The average 
of five different experiments is represented. 
4. Discussion 
The experiments performed in transfected fibroblasts 
showed that the tyrosine kinase activity of the EGF receptor 
is essential for the effect on Fru-2,6-P2 levels, like other ac-
tions of the factor, including those related to the metabolic 
activity of the cell such as glucose and amino acid uptake [31]. 
The replacement of the three main autophosphorylated tyro-
sines from the carboxy-terminal tail of the receptor with phen-
ylalanine (F3 mutants) reduces its kinase activity and inter-
nalization [32] and decreases the phosphatidylinositol 
turnover [26]. Our results show that F3 cells also have a re-
duced response to EGF, indicating that receptor autophos-
phorylation is essential to maintain the complete response to 
EGF. We also have analyzed the EGF response in fibroblasts 
with a deletion of the 214 carboxy-terminal residues of the 
receptor, including the five putative autophosphorylated tyro-
sines. This Dc214 mutant has a decreased ability to interact 
with phospholipase Cyl (PLCyl) [33], whereas the phospho-
rylation of rasGAP is similar to that obtained with the wild-
type receptor [34]. Interestingly, in this cell line the glycolytic 
response to EGF is reduced. These results suggest that the 
signaling mechanism of EGF is mediated by PLCyl rather 
than rasGAP proteins. Thus, PLCyl would be the link be-
tween the EGF receptor and the calcium-mediated stimulation 
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of glycolysis by EGF previously described in our laboratory 
[!]■ 
Our results show that, of all the ECM components tested, 
only laminin and heparin were able to modify the basal levels 
of Fru-2,6-P2. Since one of the parameters regulating the level 
of Fru-2,6-P2 is the availability of glucose, glucose transport 
inside the cell was determined, but no effect was seen in hep-
arin- or laminin-treated cells. Laminin increases the level of 
Fru-2,6-P2 up to 136-164% whereas heparin decreases the 
amount of the metabolite to 55-65%. These effects were ob-
served in confluent cultures and were caused by soluble effec-
tors in the absence of serum. This argues for a direct effect of 
both molecules rather than for indirect effects caused by 
changes of cell attachment or cell shape [16]. 
A controversy exists on the possibility that the mitogenic 
activity of laminin is contained within the EGF-like repeats of 
the molecule and mediated by the EGF receptor [16,17]. To 
study whether the EGF receptor is involved in the action of 
laminin, we analyzed the effect of this molecule in the trans-
fectants carrying different mutations of the receptor. Laminin 
was able to increase the level of Fru-2,6-P2 in all the cell lines, 
including the kinase-defective mutants. Furthermore, the stim-
ulatory effects of EGF and laminin are not additive. This fact 
indicates that, although independent of the EGF receptor, 
there is cross-talk between the mechanisms induced by lami-
nin and by EGF. A possible explanation would be that the 
pretreatment of the cells with laminin renders difficult the 
interaction of EGF with its receptor, but it has been shown 
that the binding of EGF occurs even in the presence of a 50-
fold excess of laminin [16]. Whether the effect of laminin oc-
curs through the activation of a laminin receptor such as the 
|31 integrins, as in melanoma cells [35], is unknown, although 
in this case it could provide a link between intracellular signal-
ing mechanisms mediating cell growth and metabolism. 
Finally, heparin is a complex glycosaminoglycan with a 
potent antiproliferative activity. Heparin seems to exert its 
inhibitory action by inhibiting the binding of the AP-1 tran-
scription factor to the TPA-responsive element (TRE) regions 
in the promoter of specific genes [36,37], thus blocking one or 
more steps in PK-C-dependent pathways [38,39]. PFK-2 can 
be one of these genes, since it is activated by TPA in A431 
cells and fibroblasts [1-3]. Our results indicate that heparin 
blocks the glycolytic response induced by TPA, suggesting 
that heparin may act at the transcriptional level according 
to the observations mentioned above. Nevertheless, since it 
is not known whether the PFK-2 isozyme from fibroblasts 
contains a TRE element in its promoter [40], other possibil-
ities cannot be ruled out. In any case, the decrease of Fru-2,6-
P2 caused by heparin is also visible in PK-C-depleted cells, 
indicating that this enzyme is not a step in its mechanism. The 
effect is not related to the charge density since other negatively 
charged molecules, such as chondroitin sulfate, do not alter 
Fru-2,6-P2 levels. One possibility is that heparin modifies the 
activity of a growth factor receptor, as has been described for 
the FGF receptor 4, whose tyrosine kinase activity is directly 
activated by heparin [23]. 
In conclusion, these results indicate that, similarly to solu-
ble growth factors such as EGF or oncogenes such as src, 
specific components of the ECM, such as laminin or heparin, 
can modulate the levels of Fru-2,6-P2 and, consequently, the 
glycolytic activity of the cell. Since glycolytic activation is a 
short-term response and proliferation takes place after several 
hours, a mechanism that ensures that energy is obtained from 
glucose prior to the start of cell proliferation should exist, 
independently of the molecule that initiates this process. 
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